Tarsus Pharmaceuticals (TARS)
(Delayed Data from NSDQ)
$34.51 USD
-0.09 (-0.26%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $34.46 -0.05 (-0.14%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Cash flow Statements
Fiscal Year End for Tarsus Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -135.89 | -62.09 | -13.83 | -26.81 | -4.67 |
Depreciation/Amortization & Depletion | -1.90 | -0.22 | 0.61 | 0.25 | 0.07 |
Net Change from Assets/Liabilities | 0.31 | -0.95 | 1.37 | 1.46 | 0.49 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 20.00 | 14.23 | 15.60 | 3.97 | 0.44 |
Net Cash From Operating Activities | -117.49 | -49.03 | 3.75 | -21.14 | -3.67 |
Property & Equipment | -1.50 | -0.51 | -0.59 | -0.46 | -0.18 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 146.11 | -144.12 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | -4.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 140.60 | -144.63 | -0.59 | -0.46 | -0.18 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 120.18 | 74.94 | 0.32 | 92.04 | 0.00 |
Issuance (Repayment) of Debt | 10.00 | 20.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | -0.95 | -0.30 | 39.73 | 59.45 |
Net Cash from Financing Activities | 130.18 | 93.99 | 0.02 | 131.77 | 59.45 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 153.29 | -99.67 | 3.18 | 110.18 | 55.60 |
Cash at Beginning of Period | 71.66 | 171.33 | 168.15 | 57.97 | 2.38 |
Cash at End of Period | 224.95 | 71.66 | 171.33 | 168.15 | 57.97 |
Diluted Net EPS | -4.62 | -2.52 | -0.67 | -4.32 | NA |
Fiscal Year End for Tarsus Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -69.02 | -35.73 | -135.89 | -93.99 | -54.84 |
Depreciation/Amortization & Depletion | -0.86 | 0.09 | -1.90 | -1.82 | -2.09 |
Net Change from Assets/Liabilities | 1.66 | -8.59 | 0.31 | 3.11 | 1.71 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 16.03 | 6.44 | 20.00 | 14.54 | 9.43 |
Net Cash From Operating Activities | -52.19 | -37.79 | -117.49 | -78.16 | -45.80 |
Property & Equipment | -1.21 | -0.17 | -1.50 | -1.50 | -1.13 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -141.54 | -102.05 | 146.11 | 128.26 | 76.51 |
Other Investing Activities | 0.00 | 0.00 | -4.00 | -4.00 | 0.00 |
Net Cash from Investing Activities | -142.75 | -102.22 | 140.60 | 122.75 | 75.39 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 111.45 | 108.77 | 120.18 | 100.42 | 0.52 |
Issuance (Repayment) of Debt | 75.00 | 0.00 | 10.00 | 10.00 | 5.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -35.36 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 151.09 | 108.77 | 130.18 | 110.42 | 5.52 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -43.85 | -31.24 | 153.29 | 155.01 | 35.11 |
Cash at Beginning of Period | 224.95 | 224.95 | 71.66 | 71.66 | 71.66 |
Cash at End of Period | 181.10 | 193.71 | 224.95 | 226.67 | 106.77 |
Diluted Net EPS | -0.88 | -1.01 | -1.29 | -1.28 | -1.17 |